crizanlizumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease (SCD)
Conditions
Sickle Cell Disease (SCD)
Trial Timeline
Jul 14, 2021 → Feb 14, 2024
NCT ID
NCT04662931About crizanlizumab
crizanlizumab is a approved stage product being developed by Novartis for Sickle Cell Disease (SCD). The current trial status is completed. This product is registered under clinical trial identifier NCT04662931. Target conditions include Sickle Cell Disease (SCD).
What happened to similar drugs?
3 of 20 similar drugs in Sickle Cell Disease (SCD) were approved
Approved (3) Terminated (10) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03720626 | Pre-clinical | Active |
| NCT05469828 | Phase 1/2 | Recruiting |
| NCT04662931 | Approved | Completed |
| NCT04657822 | Approved | Recruiting |
| NCT04435184 | Phase 2 | Completed |
| NCT03938454 | Phase 2 | Completed |
| NCT03474965 | Phase 2 | Completed |
| NCT03264989 | Phase 2 | Completed |
Competing Products
20 competing products in Sickle Cell Disease (SCD)